Life Sciences Cluster offers Growth Potential

Biotech Engitix Therapeutics, developers of programmes in fibrosis and solid tumours has relocated its operations to WestWorks, White City Place (WCP) following announcements of high-profile collaboration agreements with Takeda Pharmaceuticals and Morphic Therapeutic. The move to the 8,000 square feet facility of bespoke office and laboratory space in WCP will enable further growth and partnership development along with potential networking benefits. Engitix is the latest life sciences company joining the campus, with a number of biotech and global pharma organisations already occupying space in the emerging hub, including GammaDelta Therapeutics, Autolus and Synthace, as well as Novartis.

Stephen Brindle, COO of Engitix said: “Our move and expansion into this new, inspiring hub in White City is a significant milestone for Engitix. Here, we will have the ideal premises to accommodate further growth as we look to double in size in the coming years, driven by progess with both our proprietary programmes and major partnerships. As it emerges as a new centre in the field of life sciences, White City also gives us access to excellent facilities and networking opportunities for industry players.”

David Camp, CEO, Stanhope PLC, the developer and owner of WCP, stated: “We are delighted that Engitix have decided to relocate their head office to the growing life sciences cluster at the WestWorks building in White City Place. The addition of Engitix Therapeutics helps further enhance White City Place’s status as the number one location of choice for innovative, forward thinking companies in the life sciences and biotech sector.”

More information online